Eupraxia says EP-104GI kept 64% of EoE patients in remission at 52 weeks

Long-term RESOLVE trial data from the Phase 1b/2a study showed symptom relief lasting up to a year in higher-dose cohorts, with no treatment-related serious adverse events reported to date. A separate randomized Phase 2b RESOLVE study is recruiting, with interim results expected in December 2026.